Stago webinar: are FXI(a) inhibitors the anticoagulants of the future?

Back to list

This webinar will offer clinicians, clinical pathologists, researchers, and laboratory professionals an opportunity to deepen their knowledge on FXI(a) inhibitors, their potential to reshape the future of anticoagulation, and their potential impact on routine and specialized coagulation testing.
Registration mandatory logo
  • Date: Thursday, November 19th 2026
  • Time: 3pm CEST
  • Format: Live online webinar
  • Language: English
  • Speaker : Prof. Georges Jourdi
    Professor in Hematology at Paris Cité University, Clinical pathologist at Lariboisière University Hospital, AP-HP 
     
  • Registration: Register here (mandatory)
    Free registration / Replay available after the event in 6 languages


Explore the enhanced Stago Webinars experience, available now. New features, new languages, an unlimited access to all available webinars... 

Factor XI and its activated form (FXI(a)) have emerged as promising anticoagulant targets because they contribute to thrombosis while playing a limited role in normal hemostasis. This concept is supported by the relatively mild bleeding tendency observed in individuals with congenital FXI deficiency. It is then hypothesized that FXI(a) inhibition may reduce thrombotic events while preserving hemostatic function and limiting bleeding complications.

Three leading agents are currently under investigation: abelacimab, a monoclonal antibody targeting FXI/FXIa, and the oral small-molecule inhibitors asundexian and milvexian. Ongoing and completed phase 3 trials provide an initial picture of their safety and efficacy across multiple thrombotic indications.

Although routine laboratory monitoring is not required with FXI(a) inhibitors, assessment of anticoagulant activity may be useful in emergency situations such as major bleeding or urgent invasive procedure. FXI(a) inhibitors may also interfere with routine and specialized coagulation assays. Understanding these effects will be essential to ensure accurate interpretation of coagulation results in patients receiving FXI(a)-targeted therapies.

 

Stago logo

Stago webinars are developed and overseen by the Medical Affairs Department, under the scientific coordination of Dr. François Depasse, Dr. Joffrey Feriel and Dr. Marjorie Goujon.

Our Medical Affairs team supports healthcare professionals in continuously advancing their practice and strengthening the scientific value of their projects.